Tested Applications
| Positive WB detected in | human placenta tissue |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:1000 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
28053-1-AP targets PPARD in WB, IHC, ELISA applications and shows reactivity with Human samples.
| Tested Reactivity | Human |
| Cited Reactivity | human, mouse, bovine |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag27817 Product name: Recombinant human PPARD protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 1-73 aa of BC002715 Sequence: MEQPQEEAPEVREEEEKEEVAEAEGAPELNGGPQHALPSSSYTDLSRSSSPPSLLDQLQMGCDGASCGSLNME Predict reactive species |
| Full Name | peroxisome proliferator-activated receptor delta |
| Calculated Molecular Weight | 50 kDa |
| Observed Molecular Weight | 50 kDa |
| GenBank Accession Number | BC002715 |
| Gene Symbol | PPARD |
| Gene ID (NCBI) | 5467 |
| RRID | AB_2918143 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q03181 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for PPARD antibody 28053-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
PPARD Polyclonal Antibody (28053-1-AP) has 6 citations in total. The citations appear in the Journal of Translational Medicine, Antioxidants (Basel), Frontiers in Immunology, European Journal of Pharmacology, Chemico-Biological Interactions, and the Journal of Cellular Biochemistry. The related research fields include high-fat diet-induced obesity and adaptive thermogenesis, subclinical bovine mastitis and the blood-milk barrier, MASLD diagnostic modeling and drug screening, PPARδ/PPAR pathway-mediated tumor immune escape and phagocytosis, and tongue cancer invasion and survival.
| Species | Application | Title |
|---|---|---|
J Transl Med IMPA2 ameliorates high-fat diet-induced obesity by enhancing adaptive thermogenesis in a Ca²⁺-activated mitochondrial biogenesis pathway. | ||
Antioxidants (Basel) Ginsenoside Rg1 Alleviates Blood-Milk Barrier Disruption in Subclinical Bovine Mastitis by Regulating Oxidative Stress-Induced Excessive Autophagy | ||
Front Immunol Development of a diagnostic model for MASLD and identification of daidzein as the potential drug using bioinformatics analysis and experiments. | ||
Eur J Pharmacol GW501516 facilitated tumor immune escape by inhibiting phagocytosis
| ||
Chem Biol Interact f25, a novel synthetic quinoline derivative, inhibits tongue cancer cell invasion and survival by the PPAR pathway in vitro and vivo | ||
